ATE381342T1 - Prävention des zelltodes durch verwendung von segmenten der neurofilamentproteinen - Google Patents
Prävention des zelltodes durch verwendung von segmenten der neurofilamentproteinenInfo
- Publication number
- ATE381342T1 ATE381342T1 AT05003125T AT05003125T ATE381342T1 AT E381342 T1 ATE381342 T1 AT E381342T1 AT 05003125 T AT05003125 T AT 05003125T AT 05003125 T AT05003125 T AT 05003125T AT E381342 T1 ATE381342 T1 AT E381342T1
- Authority
- AT
- Austria
- Prior art keywords
- cell death
- prevention
- segments
- tissue
- neurofilament proteins
- Prior art date
Links
- 230000030833 cell death Effects 0.000 title abstract 4
- 230000002265 prevention Effects 0.000 title abstract 2
- 102000008763 Neurofilament Proteins Human genes 0.000 title 1
- 108010088373 Neurofilament Proteins Proteins 0.000 title 1
- 230000017074 necrotic cell death Effects 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29097101P | 2001-05-16 | 2001-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE381342T1 true ATE381342T1 (de) | 2008-01-15 |
Family
ID=23118262
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05003125T ATE381342T1 (de) | 2001-05-16 | 2002-05-16 | Prävention des zelltodes durch verwendung von segmenten der neurofilamentproteinen |
| AT02729699T ATE300951T1 (de) | 2001-05-16 | 2002-05-16 | Prävention des zelltodes durch verwendung der segmente der neurofilamentproteine |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02729699T ATE300951T1 (de) | 2001-05-16 | 2002-05-16 | Prävention des zelltodes durch verwendung der segmente der neurofilamentproteine |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7572450B2 (de) |
| EP (1) | EP1392347B1 (de) |
| JP (1) | JP2004529179A (de) |
| KR (1) | KR20040008177A (de) |
| CN (1) | CN1558770A (de) |
| AT (2) | ATE381342T1 (de) |
| BR (1) | BR0209630A (de) |
| CA (1) | CA2446945A1 (de) |
| DE (2) | DE60205366T2 (de) |
| DK (1) | DK1392347T3 (de) |
| ES (1) | ES2247329T3 (de) |
| WO (1) | WO2002092115A2 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7259232B1 (en) * | 2000-10-27 | 2007-08-21 | Nymox Pharmaceutical Corporation | Preferred segments of neural thread protein |
| KR100945383B1 (ko) * | 2001-05-25 | 2010-03-05 | 니목스 코포레이션 | 종양 및 세포의 제거 또는 파괴를 필요로 하는 다른질환의 치료에 효과적인 펩티드 |
| US7317077B2 (en) * | 2001-11-16 | 2008-01-08 | Nymox Pharmaceutical Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| US7544771B2 (en) * | 2005-02-23 | 2009-06-09 | Nymox Corporation | Protein and its use in diagnosing Alzheimer's disease |
| US20160361380A1 (en) * | 2015-06-12 | 2016-12-15 | Nymox Corporation | Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations |
| US11628202B2 (en) | 2015-07-24 | 2023-04-18 | Nymox Corporation | Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia |
| US10183058B2 (en) | 2016-06-17 | 2019-01-22 | Nymox Corporation | Method of preventing or reducing the progression of prostate cancer |
| US10172910B2 (en) | 2016-07-28 | 2019-01-08 | Nymox Corporation | Method of preventing or reducing the incidence of acute urinary retention |
| US10532081B2 (en) | 2016-09-07 | 2020-01-14 | Nymox Corporation | Method of ameliorating or preventing the worsening or the progression of symptoms of BPH |
| US10335453B2 (en) | 2017-03-01 | 2019-07-02 | Nymox Corporation | Compositions and methods for improving sexual function |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5948634A (en) | 1988-12-21 | 1999-09-07 | The General Hospital Coporation | Neural thread protein gene expression and detection of alzheimer's disease |
| ES2094733T3 (es) | 1988-12-21 | 1997-02-01 | Gen Hospital Corp | Deteccion de enfermedades o disfunciones neurologicas. |
| DK1564293T3 (da) | 1993-04-20 | 2009-01-12 | Gen Hospital Corp | Nervetrådproteingenekspression og detektion af Alzheimers sygdom |
| CN1300778A (zh) * | 1999-12-22 | 2001-06-27 | 上海博德基因开发有限公司 | 一种新的多肽-人神经元线蛋白15和编码这种多肽的多核苷酸 |
| CN1300779A (zh) | 1999-12-22 | 2001-06-27 | 上海博德基因开发有限公司 | 一种新的多肽-人神经元线蛋白17和编码这种多肽的多核苷酸 |
| US7259232B1 (en) * | 2000-10-27 | 2007-08-21 | Nymox Pharmaceutical Corporation | Preferred segments of neural thread protein |
| AU2002304314B2 (en) * | 2001-03-08 | 2007-09-06 | Nyomox Pharmaceutical Corporation | Using neural thread proteins to treat tumors and other hyperproliferative disorders |
-
2002
- 2002-05-16 KR KR10-2003-7014850A patent/KR20040008177A/ko not_active Abandoned
- 2002-05-16 DE DE60205366T patent/DE60205366T2/de not_active Expired - Fee Related
- 2002-05-16 DK DK02729699T patent/DK1392347T3/da active
- 2002-05-16 ES ES02729699T patent/ES2247329T3/es not_active Expired - Lifetime
- 2002-05-16 CN CNA02814029XA patent/CN1558770A/zh active Pending
- 2002-05-16 DE DE60224231T patent/DE60224231D1/de not_active Expired - Lifetime
- 2002-05-16 WO PCT/CA2002/000712 patent/WO2002092115A2/en not_active Ceased
- 2002-05-16 EP EP02729699A patent/EP1392347B1/de not_active Expired - Lifetime
- 2002-05-16 US US10/146,130 patent/US7572450B2/en not_active Expired - Fee Related
- 2002-05-16 CA CA002446945A patent/CA2446945A1/en not_active Abandoned
- 2002-05-16 BR BR0209630-7A patent/BR0209630A/pt not_active IP Right Cessation
- 2002-05-16 AT AT05003125T patent/ATE381342T1/de not_active IP Right Cessation
- 2002-05-16 JP JP2002589032A patent/JP2004529179A/ja not_active Ceased
- 2002-05-16 AT AT02729699T patent/ATE300951T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| BR0209630A (pt) | 2004-03-30 |
| EP1392347A2 (de) | 2004-03-03 |
| DE60205366D1 (de) | 2005-09-08 |
| KR20040008177A (ko) | 2004-01-28 |
| EP1392347B1 (de) | 2005-08-03 |
| DK1392347T3 (da) | 2005-12-12 |
| DE60224231D1 (de) | 2008-01-31 |
| ATE300951T1 (de) | 2005-08-15 |
| US20030004107A1 (en) | 2003-01-02 |
| WO2002092115A2 (en) | 2002-11-21 |
| DE60205366T2 (de) | 2006-05-24 |
| CA2446945A1 (en) | 2002-11-21 |
| HK1060851A1 (en) | 2004-08-27 |
| WO2002092115A3 (en) | 2003-05-15 |
| JP2004529179A (ja) | 2004-09-24 |
| US7572450B2 (en) | 2009-08-11 |
| CN1558770A (zh) | 2004-12-29 |
| ES2247329T3 (es) | 2006-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60143520D1 (de) | Inhibitoren der histon-deacetylase | |
| DE60224231D1 (de) | Prävention des Zelltodes durch Verwendung von Segmenten der Neurofilamentproteinen | |
| ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
| BR0304648A (pt) | Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia | |
| DK1233958T3 (da) | Hæmmere af histondeacetylase | |
| ATE150300T1 (de) | Hemmung der tnf - bildung | |
| BR9910296A (pt) | Novos análogos graxos para o tratamento de obesidade, hipertensão e gordura no fìgado | |
| DE60021266D1 (de) | Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine | |
| MXPA04002397A (es) | Inhibidores de histona deacetilasa. | |
| BR9811099A (pt) | Inibidores de urocinase | |
| ATE329622T1 (de) | Steigerung der antikörper-zytokin- fusionsproteinmediierten immunantwort durch mitverabreichung mit einem angiogeneseinhibitor | |
| DK0752813T3 (da) | Hæmmere af metozoan-parasit-proteaser | |
| ATE554169T1 (de) | Smad7-inhibitoren zur behandlung von krankheiten des zns | |
| ATE430572T1 (de) | Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie | |
| PT1250340E (pt) | Metodos e compostos para inibicao de mrp1 | |
| DK0706514T3 (da) | Forbindelser og fremgangsmåder til inhibering af HIV og relaterede vira | |
| ATE516027T1 (de) | Orazamid orotat zur vorbeugung von leberschäden | |
| EP0916344A3 (de) | Nef-Wirkungsinhibitor | |
| NO20006478D0 (no) | Fremgangsmåter for inhibering av korrosjon ved anvendelse av isomerer av klor-metylbenzotriazol | |
| DE69724944D1 (de) | Peptidverbindungen mit mmp- und tnf-hemmender wirkung | |
| ES2144513T3 (es) | Inhibicion de crecimiento tumoral inducido por traumatismo. | |
| ATE378069T1 (de) | Verfahren zur vorbeugung von zelltod unter verwendung von antikörpern gegen neural thread proteine | |
| DK1121108T3 (da) | Ny terapeutisk anvendelse af forbindelser med beta-3-agonistaktivitet | |
| BR0213092A (pt) | Compostos heterocìclicos de 6 elementos úteis para a inibição seletiva da cascata de coagulação | |
| ATE290878T1 (de) | Inhibierung von invasiver remodulierung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |